Jury still out on Avastin as standard in ovarian cancer
This article was originally published in Scrip
Executive Summary
Roche's Avastin (bevacizumab) has improved median progression-free survival (PFS) by close to four months in its first Phase III first-line trial in advanced ovarian cancer, but overall survival data from this trial and another ongoing study may be needed before experts decide that it is the new standard of care in the disease when used in combination with chemotherapy.
You may also be interested in...
2011 Scrip 100: A new look at cancer chemoprevention
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's Xeplion recommended for EU approval for schizophrenia
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
Pfizer's Xiapex recommended for EU approval for Dupuytren's contracture
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.